{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:49:14Z","timestamp":1787982554471,"version":"build-2784847793"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001927","name":"Nile Albright Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001927","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jo Ann Webb Fund for Angiogenesis Research"},{"name":"S. Elizabeth O\u2019Brien Trust"},{"DOI":"10.13039\/100024208","name":"Waters Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024208","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006823","name":"Boston Children's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-025-02053-2","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T15:52:44Z","timestamp":1748533964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Identification of vitronectin as a potential non-invasive biomarker of metastatic breast cancer using a label-free LC\u2013MS\/MS approach"],"prefix":"10.1186","volume":"27","author":[{"given":"Roopali","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa M.","family":"Schunkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Olivova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Geromanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Zhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gebler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelle","family":"Dagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"El-Hayek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Aldakhlallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Staffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zurakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Lotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Pories","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha A.","family":"Moses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"2053_CR1","doi-asserted-by":"publisher","unstructured":"Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A. & Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 71, 209\u2013249 (2021). https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"2053_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca Cancer J Clin. 2023;73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"Ca Cancer J Clin"},{"key":"2053_CR3","doi-asserted-by":"publisher","unstructured":"ME, J. F., Siegel, R. L., Isabelle Soerjomataram, M. & Ahmedin Jemal, D. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024). https:\/\/doi.org\/10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"key":"2053_CR4","doi-asserted-by":"publisher","first-page":"e0290174","DOI":"10.1371\/journal.pone.0290174","volume":"18","author":"Y-W Lee","year":"2023","unstructured":"Lee Y-W, Ahn S-H, Lee Y-J, Yoo T-K, Kim J, Chung IY, Kim HJ, Ko BS, Lee JW, Son BH. Survey of clinicians on the use of adjuvant therapy for premenopausal women with breast cancer. PLoS ONE. 2023;18:e0290174. https:\/\/doi.org\/10.1371\/journal.pone.0290174.","journal-title":"PLoS ONE"},{"key":"2053_CR5","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1093\/oncolo\/oyab023","volume":"27","author":"SE D\u00edaz-Casas","year":"2022","unstructured":"D\u00edaz-Casas SE, Brice\u00f1o-Morales X, Puerto-Horta LJ, Lehmann-Mosquera C, Orozco-Ospino MC, Guzm\u00e1n-AbiSaab LH, \u00c1ngel-Aristiz\u00e1bal J, Garc\u00eda-Mora M, Duarte-Torres CA, Mari\u00f1o-Lozano IF, Brice\u00f1o-Morales C, S\u00e1nchez-Pedraza R. Factors Associated with Time to Progression and Overall Survival in Patients with De Novo Metastatic Breast Cancer: A Colombian Cohort. Oncologist. 2022;27:e142\u201350. https:\/\/doi.org\/10.1093\/oncolo\/oyab023.","journal-title":"Oncologist"},{"key":"2053_CR6","doi-asserted-by":"publisher","first-page":"101282","DOI":"10.1016\/j.eclinm.2022.101282","volume":"44","author":"S Lord","year":"2022","unstructured":"Lord S, Bahlmann K, O\u2019Connell D, Kiely B, Daniels B, Pearson S, Beith J, Bulsara M, Houssami ND. novo and recurrent metastatic breast cancer\u2013A systematic review of population-level changes in survival since 1995. EClinicalMedicine. 2022;44:101282. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101282.","journal-title":"EClinicalMedicine"},{"key":"2053_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-022-06700-6","volume":"196","author":"DM File","year":"2022","unstructured":"File DM, Pascual T, Deal AM, Wheless A, Perou CM, Claire Dees E, Carey LA. Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer. Breast cancer res treatment. 2022;196:153\u201362. https:\/\/doi.org\/10.1007\/s10549-022-06700-6.","journal-title":"Breast cancer res treatment"},{"key":"2053_CR8","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.22.02222","volume":"41","author":"JK Plichta","year":"2023","unstructured":"Plichta JK, Thomas SM, Hayes DF, Chavez-MacGregor M, Allison K, De Los Santos J, Fowler AM, Giuliano AE, Sharma P, Smith BD. Novel prognostic staging system for patients with de novo metastatic breast cancer. J Clin Oncology. 2023;41:2546\u201360. https:\/\/doi.org\/10.1200\/JCO.22.02222.","journal-title":"J Clin Oncology"},{"key":"2053_CR9","doi-asserted-by":"publisher","unstructured":"Pedersen, R. N., Esen, B. \u00d6., Mellemkj\u00e6r, L., Christiansen, P., Ejlertsen, B., Lash, T. L., N\u00f8rgaard, M. & Cronin-Fenton, D. The incidence of breast cancer recurrence 10\u201332 years after primary diagnosis. JNCI: Journal of the National Cancer Institute 2022;114, 391\u2013399. https:\/\/doi.org\/10.1093\/jnci\/djab202","DOI":"10.1093\/jnci\/djab202"},{"key":"2053_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-6311-z","volume":"19","author":"R Wang","year":"2019","unstructured":"Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. 2019;19:1\u201312. https:\/\/doi.org\/10.1186\/s12885-019-6311-z.","journal-title":"BMC Cancer"},{"key":"2053_CR11","doi-asserted-by":"publisher","unstructured":"Guo, Y., Arciero, C. A., Jiang, R., Behera, M., Peng, L. & Li, X. Different Breast Cancer Subtypes Show Different Metastatic Patterns: A Study from A Large Public Database. Asian Pac J Cancer Prev 2020;21, 3587\u20133593. https:\/\/doi.org\/10.31557\/apjcp.2020.21.12.3587","DOI":"10.31557\/apjcp.2020.21.12.3587"},{"key":"2053_CR12","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10549-015-3352-0","volume":"150","author":"CD Savci-Heijink","year":"2015","unstructured":"Savci-Heijink CD, Halfwerk H, Hooijer GK, Horlings HM, Wesseling J, van de Vijver MJ. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 2015;150:547\u201357. https:\/\/doi.org\/10.1007\/s10549-015-3352-0.","journal-title":"Breast Cancer Res Treat"},{"key":"2053_CR13","doi-asserted-by":"publisher","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA: a cancer journal for clinicians 2019;69, 7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","DOI":"10.3322\/caac.21551"},{"key":"2053_CR14","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios C, Cortes J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz S. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer\u2606. Ann Oncol. 2021;32:1475\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019.","journal-title":"Ann Oncol"},{"key":"2053_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.25122\/jml-2021-0108","volume":"15","author":"A Baranova","year":"2022","unstructured":"Baranova A, Krasnoselskyi M, Starikov V, Kartashov S, Zhulkevych I, Vlasenko V, Oleshko K, Bilodid O, Sadchikova M, Vinnyk Y. Triple-negative breast cancer: current treatment strategies and factors of negative prognosis. J Med Life. 2022;15:153. https:\/\/doi.org\/10.25122\/jml-2021-0108.","journal-title":"J Med Life"},{"key":"2053_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000492929","volume":"3","author":"EM Schunkert","year":"2018","unstructured":"Schunkert EM, Zhao W, Z\u00e4nker K. Breast cancer recurrence risk assessment: is non-invasive monitoring an option? Biomedicine hub. 2018;3:1\u201317. https:\/\/doi.org\/10.1159\/000492929.","journal-title":"Biomedicine hub"},{"key":"2053_CR17","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/00007611-198809000-00011","volume":"81","author":"V Patanaphan","year":"1988","unstructured":"Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J. 1988;81:1109\u201312.","journal-title":"South Med J"},{"key":"2053_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07064-0","volume":"20","author":"J Wang","year":"2020","unstructured":"Wang J, Cai Y, Yu F, Ping Z, Liu L. Body mass index increases the lymph node metastasis risk of breast cancer: a dose-response meta-analysis with 52904 subjects from 20 cohort studies. BMC Cancer. 2020;20:1\u201311. https:\/\/doi.org\/10.1186\/s12885-020-07064-0.","journal-title":"BMC Cancer"},{"key":"2053_CR19","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1158\/1055-9965.EPI-22-0013","volume":"31","author":"LT Olsson","year":"2022","unstructured":"Olsson LT, Walens A, Hamilton AM, Benefield HC, Fleming JM, Carey LA, Hursting SD, Williams KP, Troester MA. Obesity and Breast Cancer Metastasis across Genomic Subtypes. Cancer Epidemiol Biomark Prev. 2022;31:1944\u201351. https:\/\/doi.org\/10.1158\/1055-9965.EPI-22-0013.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2053_CR20","doi-asserted-by":"publisher","unstructured":"Borri, F. & Granaglia, A. in Seminars in cancer biology. 136\u2013145 (Elsevier). https:\/\/doi.org\/10.1016\/j.semcancer.2020.06.005","DOI":"10.1016\/j.semcancer.2020.06.005"},{"key":"2053_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.978985","volume":"13","author":"J-H Fan","year":"2023","unstructured":"Fan J-H, Zhang S, Yang H, Yi Z-B, Ouyang Q-C, Yan M, Wang X-J, Hu X-C, Jiang Z-F, Huang T. Molecular subtypes predict the preferential site of distant metastasis in advanced breast cancer: a nationwide retrospective study. Front Oncol. 2023;13: 978985. https:\/\/doi.org\/10.3389\/fonc.2023.978985.","journal-title":"Front Oncol"},{"key":"2053_CR22","doi-asserted-by":"publisher","first-page":"2203699","DOI":"10.1002\/advs.202203699","volume":"10","author":"Y Zou","year":"2023","unstructured":"Zou Y, Ye F, Kong Y, Hu X, Deng X, Xie J, Song C, Ou X, Wu S, Wu L. The single-cell landscape of intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast cancer. Advanced Science. 2023;10:2203699. https:\/\/doi.org\/10.1002\/advs.202203699.","journal-title":"Advanced Science"},{"key":"2053_CR23","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1200\/JCO.21.02062","volume":"40","author":"RN Pedersen","year":"2022","unstructured":"Pedersen RN, Mellemkj\u00e6r L, Ejlertsen B, N\u00f8rgaard M, Cronin-Fenton DP. Mortality after late breast cancer recurrence in Denmark. J Clin Oncol. 2022;40:1450\u201363. https:\/\/doi.org\/10.1200\/JCO.21.02062.","journal-title":"J Clin Oncol"},{"key":"2053_CR24","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1200\/JCO.2012.45.9859","volume":"31","author":"JL Khatcheressian","year":"2013","unstructured":"Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:961\u20135. https:\/\/doi.org\/10.1200\/JCO.2012.45.9859.","journal-title":"J Clin Oncol"},{"key":"2053_CR25","doi-asserted-by":"publisher","unstructured":"Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F. & Bast, R. C., Jr. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25, 5287\u20135312. https:\/\/doi.org:https:\/\/doi.org\/10.1200\/jco.2007.14.2364","DOI":"10.1200\/jco.2007.14.2364"},{"key":"2053_CR26","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1001\/jama.281.17.1586","volume":"281","author":"D Palli","year":"1999","unstructured":"Palli D, Russo A, Saieva C, Ciatto S, Del Turco MR, Distante V, Pacini P. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. JAMA. 1999;281:1586\u20131586. https:\/\/doi.org\/10.1001\/jama.281.17.1586.","journal-title":"JAMA"},{"key":"2053_CR27","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1093\/annonc\/6.suppl_2.s41","volume":"6","author":"A Liberati","year":"1995","unstructured":"Liberati A, Investigators G. The GIVIO trial on the impact of follow-up care on survival and quality of life in breast cancer patients. Ann Oncol. 1995;6:S41\u20136. https:\/\/doi.org\/10.1093\/annonc\/6.suppl_2.s41.","journal-title":"Ann Oncol"},{"key":"2053_CR28","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38:2830\u20138. https:\/\/doi.org\/10.1200\/JCO.20.00818.","journal-title":"J Clin Oncol"},{"key":"2053_CR29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S1470-2045(20)30537-4","volume":"22","author":"A Chalkidou","year":"2021","unstructured":"Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, Coker B, Patrick H, Powell H, Berry L. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021;22:98\u2013106. https:\/\/doi.org\/10.1016\/S1470-2045(20)30537-4.","journal-title":"Lancet Oncol"},{"key":"2053_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40291-020-00482-7","volume":"24","author":"YY Syed","year":"2020","unstructured":"Syed YY. Oncotype DX breast recurrence score\u00ae: a review of its use in early-stage breast cancer. Mol Diagn Ther. 2020;24:621\u201332. https:\/\/doi.org\/10.1007\/s40291-020-00482-7.","journal-title":"Mol Diagn Ther"},{"key":"2053_CR31","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4048\/jbc.2020.23.e36","volume":"23","author":"K Kim","year":"2020","unstructured":"Kim K, Jung J, Shin KH, Kim JH, Chang JH, Kim SS, Kim H, Park W, Kim YB, Chang JS. Impact of oncotype DX recurrence score on the patterns of locoregional recurrence in breast cancer (Korean radiation oncology group 19\u201306). J Breast Cancer. 2020;23:314. https:\/\/doi.org\/10.4048\/jbc.2020.23.e36.","journal-title":"J Breast Cancer"},{"key":"2053_CR32","doi-asserted-by":"publisher","unstructured":"Lopes Cardozo, J., Schmidt, M. K., van\u2019t Veer, L. J., Cardoso, F., Poncet, C., Rutgers, E. J. & Drukker, C. A. Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer. Breast Cancer Research and Treatment 2021;189, 399\u2013410. https:\/\/doi.org\/10.1007\/s10549-021-06315-3","DOI":"10.1007\/s10549-021-06315-3"},{"key":"2053_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/1878-0261.13021","volume":"16","author":"F Bras\u00f3-Maristany","year":"2022","unstructured":"Bras\u00f3-Maristany F, Par\u00e9 L, Chic N, Mart\u00ednez-S\u00e1ez O, Pascual T, Mallafr\u00e9-Larrosa M, Schettini F, Gonz\u00e1lez-Farr\u00e9 B, Sanfeliu E, Mart\u00ednez D. Gene expression profiles of breast cancer metastasis according to organ site. Mol Oncol. 2022;16:69\u201387. https:\/\/doi.org\/10.1002\/1878-0261.13021.","journal-title":"Mol Oncol"},{"key":"2053_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10549-016-3741-z","volume":"156","author":"CD Savci-Heijink","year":"2016","unstructured":"Savci-Heijink CD, Halfwerk H, Koster J, van de Vijver MJ. A novel gene expression signature for bone metastasis in breast carcinomas. Breast Cancer Res Treat. 2016;156:249\u201359. https:\/\/doi.org\/10.1007\/s10549-016-3741-z.","journal-title":"Breast Cancer Res Treat"},{"key":"2053_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102434","volume":"109","author":"F De Rose","year":"2022","unstructured":"De Rose F, Meduri B, De Santis MC, Ferro A, Marino L, Colciago RR, Gregucci F, Vanoni V, Apolone G, Di Cosimo S. Rethinking breast cancer follow-up based on individual risk and recurrence management. Cancer Treat Rev. 2022;109: 102434. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102434.","journal-title":"Cancer Treat Rev"},{"key":"2053_CR36","doi-asserted-by":"publisher","first-page":"117727192311902","DOI":"10.1177\/11772719231190218","volume":"18","author":"A Shama","year":"2023","unstructured":"Shama A, Soni T, Jawanda IK, Upadhyay G, Sharma A, Prabha V. The latest developments in using proteomic biomarkers from urine and serum for non-invasive disease diagnosis and prognosis. Biomarker Insights. 2023;18:11772719231190218. https:\/\/doi.org\/10.1177\/11772719231190218.","journal-title":"Biomarker Insights"},{"key":"2053_CR37","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.3390\/cancers13112652","volume":"13","author":"M Oshi","year":"2021","unstructured":"Oshi M, Murthy V, Takahashi H, Huyser M, Okano M, Tokumaru Y, Rashid OM, Matsuyama R, Endo I, Takabe K. Urine as a source of liquid biopsy for cancer. Cancers. 2021;13:2652. https:\/\/doi.org\/10.3390\/cancers13112652.","journal-title":"Cancers"},{"key":"2053_CR38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3233\/CBM-190575","volume":"27","author":"A Ritter","year":"2020","unstructured":"Ritter A, Hirschfeld M, Berner K, Jaeger M, Grundner-Culemann F, Schlosser P, Asberger J, Weiss D, Noethling C, Mayer S. Discovery of potential serum and urine-based microRNA as minimally-invasive biomarkers for breast and gynecological cancer. Cancer Biomark. 2020;27:225\u201342. https:\/\/doi.org\/10.3233\/CBM-190575.","journal-title":"Cancer Biomark"},{"key":"2053_CR39","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1158\/1055-9965.EPI-07-0365","volume":"17","author":"SE Pories","year":"2008","unstructured":"Pories SE, Zurakowski D, Roy R, Lamb CC, Raza S, Exarhopoulos A, Scheib RG, Schumer S, Lenahan C, Borges V, Louis G, Anand A, Isakovich N, Hirshfield-Bartek J, Wewer UM, Moses MA. Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomark Prev. 2008;17:1034\u201342. https:\/\/doi.org\/10.1158\/1055-9965.EPI-07-0365.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2053_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-1284-z","volume":"15","author":"A Jedinak","year":"2015","unstructured":"Jedinak A, Curatolo A, Zurakowski D, Dillon S, Bhasin MK, Libermann TA, Roy R, Sachdev M, Loughlin KR, Moses MA. Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer. BMC Cancer. 2015;15:1\u20139. https:\/\/doi.org\/10.1186\/s12885-015-1284-z.","journal-title":"BMC Cancer"},{"key":"2053_CR41","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1158\/1078-0432.CCR-07-1253","volume":"14","author":"ER Smith","year":"2008","unstructured":"Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res. 2008;14:2378\u201386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1253.","journal-title":"Clin Cancer Res"},{"key":"2053_CR42","doi-asserted-by":"publisher","unstructured":"Roy, R., Wewer, U. M., Zurakowski, D., Pories, S. E. & Moses, M. A. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004;279, 51323\u201351330. https:\/\/doi.org:https:\/\/doi.org\/10.1074\/jbc.M409565200","DOI":"10.1074\/jbc.M409565200"},{"key":"2053_CR43","first-page":"1395","volume":"58","author":"MA Moses","year":"1998","unstructured":"Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Can Res. 1998;58:1395\u20139.","journal-title":"Can Res"},{"key":"2053_CR44","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1038\/bjc.2014.462","volume":"111","author":"R Roy","year":"2014","unstructured":"Roy R, Zurakowski D, Wischhusen J, Frauenhoffer C, Hooshmand S, Kulke M, Moses M. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer. 2014;111:1772\u20139. https:\/\/doi.org\/10.1038\/bjc.2014.462.","journal-title":"Br J Cancer"},{"key":"2053_CR45","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3390\/cancers12082109","volume":"12","author":"SL Wood","year":"2020","unstructured":"Wood SL, Brown JE. Personal medicine and bone metastases: biomarkers, micro-RNAs and bone metastases. Cancers. 2020;12:2109. https:\/\/doi.org\/10.3390\/cancers12082109.","journal-title":"Cancers"},{"key":"2053_CR46","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3760\/cma.j.issn.0253-3766.2016.09.011","volume":"38","author":"C Wu","year":"2016","unstructured":"Wu C, Ma L, Zhu J, Liu J, Cheng Y. Clinical significance of combined detection of urine NTX and serum ICTP for breast cancer patients with bone metastases. Zhonghua Zhong liu za zhi [Chinese Journal of Oncology]. 2016;38:693\u20137. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3766.2016.09.011.","journal-title":"Zhonghua Zhong liu za zhi [Chinese Journal of Oncology]"},{"key":"2053_CR47","doi-asserted-by":"publisher","unstructured":"Jung, K, Lein, M. Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 2014;1846, 425\u2013438. https:\/\/doi.org\/10.1016\/j.bbcan.2014.09.001","DOI":"10.1016\/j.bbcan.2014.09.001"},{"key":"2053_CR48","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1158\/1055-9965.EPI-05-0909","volume":"15","author":"DJ Leeming","year":"2006","unstructured":"Leeming DJ, Delling G, Koizumi M, Henriksen K, Karsdal MA, Li B, Qvist P, Tank\u00f3 LB, Byrjalsen I. Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion. Cancer Epidemiol Biomark Prev. 2006;15:1392\u20135. https:\/\/doi.org\/10.1158\/1055-9965.EPI-05-0909.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2053_CR49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/1055-9965.EPI-05-0492","volume":"15","author":"DJ Leeming","year":"2006","unstructured":"Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tank\u00f3 LB. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomark Prev. 2006;15:32\u20138. https:\/\/doi.org\/10.1158\/1055-9965.EPI-05-0492.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2053_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1741-7015-10-51","volume":"10","author":"DG Altman","year":"2012","unstructured":"Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med. 2012;10:1\u201339. https:\/\/doi.org\/10.1186\/1741-7015-10-51.","journal-title":"BMC Med"},{"key":"2053_CR51","doi-asserted-by":"publisher","unstructured":"Sauerbrei, W., Taube, S. E., McShane, L. M., Cavenagh, M. M. & Altman, D. G. Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. JNCI: Journal of the National Cancer Institute 110, 803\u2013811 (2018). https:\/\/doi.org\/10.1093\/jnci\/djy088","DOI":"10.1093\/jnci\/djy088"},{"key":"2053_CR52","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1212\/WNL.0000000000013001","volume":"98","author":"CC Daisy","year":"2022","unstructured":"Daisy CC, Varinos S, Howell DR, Kaplan K, Mannix R, Meehan WP, Wang F, Berkstresser B, Lee RS, Froehlich JW. Proteomic discovery of noninvasive biomarkers associated with sport-related concussions. Neurology. 2022;98:e186\u201398. https:\/\/doi.org\/10.1212\/WNL.0000000000013001.","journal-title":"Neurology"},{"key":"2053_CR53","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/elps.200800630","volume":"30","author":"M Gilar","year":"2009","unstructured":"Gilar M, Olivova P, Chakraborty AB, Jaworski A, Geromanos SJ, Gebler JC. Comparison of 1-D and 2-D LC MS\/MS methods for proteomic analysis of human serum. Electrophoresis. 2009;30:1157\u201367. https:\/\/doi.org\/10.1002\/elps.200800630.","journal-title":"Electrophoresis"},{"key":"2053_CR54","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1074\/mcp.M500230-MCP200","volume":"5","author":"JC Silva","year":"2006","unstructured":"Silva JC, Gorenstein MV, Li G-Z, Vissers JP, Geromanos SJ. Absolute quantification of proteins by LCMSE: A virtue of parallel MS acquisition* S. Mol Cell Proteomics. 2006;5:144\u201356. https:\/\/doi.org\/10.1074\/mcp.M500230-MCP200.","journal-title":"Mol Cell Proteomics"},{"key":"2053_CR55","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/pmic.200800562","volume":"9","author":"SJ Geromanos","year":"2009","unstructured":"Geromanos SJ, Vissers JP, Silva JC, Dorschel CA, Li GZ, Gorenstein MV, Bateman RH, Langridge JI. The detection, correlation, and comparison of peptide precursor and product ions from data independent LC-MS with data dependant LC-MS\/MS. Proteomics. 2009;9:1683\u201395. https:\/\/doi.org\/10.1002\/pmic.200800562.","journal-title":"Proteomics"},{"key":"2053_CR56","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/pmic.200800564","volume":"9","author":"GZ Li","year":"2009","unstructured":"Li GZ, Vissers JP, Silva JC, Golick D, Gorenstein MV, Geromanos SJ. Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures. Proteomics. 2009;9:1696\u2013719. https:\/\/doi.org\/10.1002\/pmic.200800564.","journal-title":"Proteomics"},{"key":"2053_CR57","doi-asserted-by":"publisher","unstructured":"Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., Jensen, L. J. & Mering, C. V. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019;47, D607-d613. https:\/\/doi.org:https:\/\/doi.org\/10.1093\/nar\/gky1131","DOI":"10.1093\/nar\/gky1131"},{"key":"2053_CR58","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.jpedsurg.2020.01.003","volume":"55","author":"SJ Staffa","year":"2020","unstructured":"Staffa SJ, Zurakowski D. Strategies in adjusting for multiple comparisons: a primer for pediatric surgeons. J Pediatr Surg. 2020;55:1699\u2013705. https:\/\/doi.org\/10.1016\/j.jpedsurg.2020.01.003.","journal-title":"J Pediatr Surg"},{"key":"2053_CR59","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/RTI.0b013e318281db88","volume":"28","author":"D Zurakowski","year":"2013","unstructured":"Zurakowski D, Johnson VM, Lee EY. Biostatistics in clinical decision making for cardiothoracic radiologists. J Thorac Imaging. 2013;28:368\u201375. https:\/\/doi.org\/10.1097\/RTI.0b013e318281db88.","journal-title":"J Thorac Imaging"},{"key":"2053_CR60","doi-asserted-by":"publisher","unstructured":"Aitekenov, S., Gaipov, A. & Bukasov, R. Review: Detection and quantification of proteins in human urine. Talanta 223, 121718 (2021). https:\/\/doi.org\/10.1016\/j.talanta.2020.121718","DOI":"10.1016\/j.talanta.2020.121718"},{"key":"2053_CR61","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1200\/jco.2009.23.5556","volume":"27","author":"R Roy","year":"2009","unstructured":"Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27:5287\u201397. https:\/\/doi.org\/10.1200\/jco.2009.23.5556.","journal-title":"J Clin Oncol"},{"key":"2053_CR62","doi-asserted-by":"publisher","first-page":"6610","DOI":"10.1158\/1078-0432.CCR-08-1136","volume":"14","author":"R Roy","year":"2008","unstructured":"Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, Zurakowski D, Moses MA. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res. 2008;14:6610\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1136.","journal-title":"Clin Cancer Res"},{"key":"2053_CR63","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1158\/1078-0432.CCR-04-2391","volume":"11","author":"CA Fern\u00e1ndez","year":"2005","unstructured":"Fern\u00e1ndez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9\/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res. 2005;11:5390\u20135. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2391.","journal-title":"Clin Cancer Res"},{"key":"2053_CR64","doi-asserted-by":"publisher","first-page":"37258","DOI":"10.1074\/jbc.M106089200","volume":"276","author":"L Yan","year":"2001","unstructured":"Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B\/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL): modulation of MMP-9 activity by NGAL. J Biol Chem. 2001;276:37258\u201365. https:\/\/doi.org\/10.1074\/jbc.M106089200.","journal-title":"J Biol Chem"},{"key":"2053_CR65","doi-asserted-by":"publisher","unstructured":"Ye, B., Skates, S., Mok, S. C., Horick, N. K., Rosenberg, H. F., Vitonis, A., Edwards, D., Sluss, P., Han, W. K., Berkowitz, R. S. & Cramer, D. W. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 2006;12, 432\u2013441. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-05-0461","DOI":"10.1158\/1078-0432.Ccr-05-0461"},{"key":"2053_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/153537020422900101","volume":"229","author":"E Sapi","year":"2004","unstructured":"Sapi E. The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update. Exp Biol Med (Maywood). 2004;229:1\u201311. https:\/\/doi.org\/10.1177\/153537020422900101.","journal-title":"Exp Biol Med (Maywood)"},{"key":"2053_CR67","doi-asserted-by":"publisher","unstructured":"Katafigioti, A., Katafigiotis, I., Sfoungaristos, S., Alamanis, C., Stravodimos, K., Anastasiou, I., Roumelioti, E., Duvdevani, M. & Constantinides, C. In the search of novel urine biomarkers for the early diagnosis of prostate cancer. Intracellular or secreted proteins as the target group? Where and how to search for possible biomarkers useful in the everyday clinical practice. Archivio Italiano di Urologia e Andrologia 2016;88, 195\u2013200. https:\/\/doi.org\/10.4081\/aiua.2016.3.195","DOI":"10.4081\/aiua.2016.3.195"},{"key":"2053_CR68","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1158\/2767-9764.CRC-24-0218","volume":"4","author":"S Verma","year":"2024","unstructured":"Verma S, Giagnocavo SD, Curtin MC, Arumugam M, Osburn-Staker SM, Wang G, Atkinson A, Nix DA, Lum DH, Cox JE. Zinc-alpha-2-glycoprotein secreted by triple-negative breast cancer promotes Peritumoral fibrosis. Cancer Research Communications. 2024;4:1655\u201366. https:\/\/doi.org\/10.1158\/2767-9764.CRC-24-0218.","journal-title":"Cancer Research Communications"},{"key":"2053_CR69","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/1078-0432.CCR-23-2326","volume":"30","author":"M Coakley","year":"2024","unstructured":"Coakley M, Villacampa G, Sritharan P, Swift C, Dunne K, Kilburn L, Goddard K, Pipinikas C, Rojas P, Emmett W. Comparison of circulating tumor DNA assays for molecular residual disease detection in early-stage triple-negative breast cancer. Clin Cancer Res. 2024;30:895\u2013903. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2326.","journal-title":"Clin Cancer Res"},{"key":"2053_CR70","doi-asserted-by":"crossref","unstructured":"Garcia-Murillas, I., Cutts, R. J., Walsh-Crestani, G., Phillips, E., Hrebien, S., Dunne, K., Sidhu, K., Daber, R., Hubert, B. & Graybill, C. Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer. Breast Cancer Research and Treatment, 2024;1\u201310. https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07508-2","DOI":"10.1007\/s10549-024-07508-2"},{"key":"2053_CR71","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-23-0757","volume":"29","author":"AJ Medford","year":"2023","unstructured":"Medford AJ, Moy B, Spring LM, Hurvitz SA, Turner NC, Bardia A. Molecular residual disease in breast cancer: detection and therapeutic interception. Clin Cancer Res. 2023;29:4540\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0757.","journal-title":"Clin Cancer Res"},{"key":"2053_CR72","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.breast.2020.05.005","volume":"52","author":"J Hing","year":"2020","unstructured":"Hing J, Mok C, Tan P, Sudhakar S, Seah C, Lee W, Tan S. Clinical utility of tumour marker velocity of cancer antigen 15\u20133 (CA 15\u20133) and carcinoembryonic antigen (CEA) in breast cancer surveillance. The Breast. 2020;52:95\u2013101. https:\/\/doi.org\/10.1016\/j.breast.2020.05.005.","journal-title":"The Breast"},{"key":"2053_CR73","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cca.2021.08.027","volume":"523","author":"J Zhang","year":"2021","unstructured":"Zhang J, Wei Q, Dong D, Ren L. The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer. Clin Chim Acta. 2021;523:19\u201325. https:\/\/doi.org\/10.1016\/j.cca.2021.08.027.","journal-title":"Clin Chim Acta"},{"key":"2053_CR74","doi-asserted-by":"crossref","unstructured":"Jia, L., Li, G., Ma, N., Zhang, A., Zhou, Y., Ren, L. & Dong, D. Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction. BMC cancer 2022;22, 760. https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09864-y","DOI":"10.1186\/s12885-022-09864-y"},{"key":"2053_CR75","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1021\/pr100747p","volume":"9","author":"W Cho","year":"2010","unstructured":"Cho W, Jung K, Regnier FE. Sialylated Lewis x antigen bearing glycoproteins in human plasma. J Proteome Res. 2010;9:5960\u20138. https:\/\/doi.org\/10.1021\/pr100747p.","journal-title":"J Proteome Res"},{"key":"2053_CR76","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00432-010-0974-9","volume":"137","author":"M Kadowaki","year":"2011","unstructured":"Kadowaki M, Sangai T, Nagashima T, Sakakibara M, Yoshitomi H, Takano S, Sogawa K, Umemura H, Fushimi K, Nakatani Y, Nomura F, Miyazaki M. Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach. J Cancer Res Clin Oncol. 2011;137:1105\u201315. https:\/\/doi.org\/10.1007\/s00432-010-0974-9.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2053_CR77","doi-asserted-by":"publisher","unstructured":"Radwan, A. F., Ismael, O. E., Fawzy, A. & El-Mesallamy, H. O. Evaluation of serum integrin \u03b1v\u03b23 & Vitronectin in the early diagnosis of breast Cancer. Clin Lab 2019;65. https:\/\/doi.org\/10.7754\/Clin.Lab.2019.181219","DOI":"10.7754\/Clin.Lab.2019.181219"},{"key":"2053_CR78","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/ijc.30202","volume":"139","author":"I Ortega-Mart\u00ednez","year":"2016","unstructured":"Ortega-Mart\u00ednez I, Gardeazabal J, Erramuzpe A, Sanchez-Diez A, Cort\u00e9s J, Garc\u00eda-V\u00e1zquez MD, P\u00e9rez-Yarza G, Izu R, Lu\u00edsD\u00edaz-Ram\u00f3n J, de la Fuente IM, Asumendi A, Boyano MD. Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I-II early-stage melanoma. Int J Cancer. 2016;139:1598\u2013607. https:\/\/doi.org\/10.1002\/ijc.30202.","journal-title":"Int J Cancer"},{"key":"2053_CR79","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1146\/annurev.cb.07.110191.001423","volume":"7","author":"KT Preissner","year":"1991","unstructured":"Preissner KT. Structure and biological role of vitronectin. Annu Rev Cell Biol. 1991;7:275\u2013310. https:\/\/doi.org\/10.1146\/annurev.cb.07.110191.001423.","journal-title":"Annu Rev Cell Biol"},{"key":"2053_CR80","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1042\/cbi20090331","volume":"34","author":"L Heyman","year":"2010","unstructured":"Heyman L, Leroy-Dudal J, Fernandes J, Seyer D, Dutoit S, Carreiras F. Mesothelial vitronectin stimulates migration of ovarian cancer cells. Cell Biol Int. 2010;34:493\u2013502. https:\/\/doi.org\/10.1042\/cbi20090331.","journal-title":"Cell Biol Int"},{"key":"2053_CR81","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1172\/jci33775","volume":"118","author":"HA Kenny","year":"2008","unstructured":"Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008;118:1367\u201379. https:\/\/doi.org\/10.1172\/jci33775.","journal-title":"J Clin Invest"},{"key":"2053_CR82","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000360085","volume":"51","author":"R Li","year":"2014","unstructured":"Li R, Luo M, Ren M, Chen N, Xia J, Deng X, Zeng M, Yan K, Luo T, Wu J. Vitronectin regulation of vascular endothelial growth factor-mediated angiogenesis. J Vasc Res. 2014;51:110\u20137. https:\/\/doi.org\/10.1159\/000360085.","journal-title":"J Vasc Res"},{"key":"2053_CR83","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1177\/44.3.8648088","volume":"44","author":"D Seiffert","year":"1996","unstructured":"Seiffert D. Detection of vitronectin in mineralized bone matrix. J Histochem Cytochem. 1996;44:275\u201380. https:\/\/doi.org\/10.1177\/44.3.8648088.","journal-title":"J Histochem Cytochem"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02053-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02053-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02053-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T15:52:51Z","timestamp":1748533971000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-025-02053-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2053"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02053-2","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Specimens were obtained prior to surgical or other therapeutic intervention according to the bioethical guidelines of the Institutional Review Board at Mount Auburn Hospital and Boston Children\u2019s Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not appliable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}